high - throughput screening(passive) was discovered byPrCP ) inhibitors

coadministration with outer membrane permeability enhancers profoundly sensitizes Escherichia colito designedLpxH inhibitors

Lam et al used information from x - ray crystal structure studies of HIV protease inhibitor complexesto designnonpeptide inhibitors

to help folks with high levels of dangerous cholesterol who ca n’t get their situation beneath control with statins such as Pfizer Inc. ’s Lipitor(passive) are designedPCSK9 inhibitors

to increase levels of high - density lipoprotein ( HDL ) cholesterol - which is sometimes described as ' good ' cholesterol with a protective cardiovascular effect although that hypothesis has been dented by the CETP class failures(passive) are designedCETP inhibitors

Up till now , many efforts have madeto discovernecroptosis inhibitors

Asn663 played key rolesto designPDE5 inhibitors

to stop the repair process in cancer cells , leaving the damaged cells to die(passive) are designedPARP inhibitors

pivotal trial AstraZeneca EVP : Brexit is hindering our hiring Forge Therapeutics , Evotec launch platformto discovermetalloenzyme inhibitors

to stop the proteasomes from recycling proteins inside cancer cells , causing a toxic protein overload that may kill the cell(passive) are designedProteasome inhibitors

based on dioxabicyclo[3.2.1 ] octane with the aim to search new lead molecule(passive) were designedSGLT2 inhibitors

10.1016 / j.bbrc.2017.03.122 Sigma-2 ligands andtriggerPARP inhibitors

to overcome a cancer cell 's ability to repair the damaged DNA(passive) are designedPARP inhibitors

protein - protein interactions ... extremely challengingto designHIF-1α inhibitors

to target cancers that already have existing defects in DNA repairs(passive) are designedPARP inhibitors

Donahue Timothy R Histoneprovokedeacetylase inhibitors

to raise HDL - cholesterol levels or what is known as “ good ” cholesterol(passive) are designedCETP inhibitors

to be screened against the Molecular Libraries Small Molecule Repository ( MLSMRto discoverTDP-43 inhibitors

AstraZeneca ’s first - to - market Lynparza(passive) led byPARP inhibitors

an analysis of the binding site of thapsigargin AU - Liljefors , Tommy AU - Ley , Steven V. AU - Oliver , Steven F. AU - Antonello , Alessandra AU - Smith , Martin D. AU - Christensen(passive) designed by-ATPase inhibitors

fragment - based screening Angeline C.-H. Lee , Pondy Murugappan Ramanujulu , Anders Poulsen , Meredith Williams , Stéphanie Blanchard , Diana M. Ma(passive) discovered byPDK1 inhibitors

an analysis of the binding site of thapsigargin Helmer Søhoel , Tommy Liljefors , Steven V. Ley , Steven F. Oliver , Alessandra Antonello , Martin D. Smith , Carl Erik Olsen , John Tod Isaacs , S. Brøgger Christensen Analysis of molecular interaction fields based on the published crystal structure of thapsigargin bound to the sarco / endoplasmatic reticulum(passive) designed by-ATPase inhibitors

to break down endocannabinoids , including anandamide , in the brain and are also being investigated for use in the treatment of chronic pain(passive) are designedFAAH inhibitors

to disable those enzymes along with enzymes damaged by chemotherapy(passive) are designedPARP inhibitors

dithiocarbamate complexescreateproteasome inhibitors

obviously(passive) are ... designedRenin inhibitors

they block activation of angiotensin II AT1 receptorspreventingangiotensin Renin inhibitors

inactivation of SLFN11(passive) caused byPARP inhibitors

to slow the inactivation of incretin hormones glucagon - like peptide-1 ( GLP ) GLP-1 and glucose - dependent insulinotropic peptide ( GIP(passive) are designedDPP-4 inhibitors

Treatment of Tg MEF withledproteasome inhibitors

I - Improving capacityto preventPDE-5 inhibitors

to disable key enzymes that cancer cells use to repair DNA damage , including damage inflicted by chemotherapy , and to promote cancer cell death(passive) are designedPARP inhibitors

Revlimid and Velcade , and including Kyprolis , Ninlaro and Pomalyst(passive) led byproteasome inhibitors

to disable DNA repair pathways in cancer cells , which make it difficult for those cells to survive(passive) are designedPARP inhibitors

to improve HDL plasma levels , by decreasing flux of cholesterol into apoB - containing lipoproteins from HDL(passive) have been designedCETP ) inhibitors

to reduce the risk of cardiovascular diseases like atherosclerosis(passive) are designedCETP inhibitors

to prevent the breakdown of the incretin glucagon - like peptide 1 ( GLP-1 ) by inhibiting the protease DPP-4 thereby increasing insulin secretion in the pancreas(passive) have been designedDPP-4 ) inhibitors

to inhibit the activity of “ urease(passive) are designedUrease inhibitors

to inhibit the activity of PDE4 , the enzyme which breaks down neuronal(passive) are designedPDE4 inhibitors

to bind to CTLA - A and prevent its function , which boosts the immune system ’s response(passive) are designedCTLA-4 inhibitors